pith. sign in

arxiv: 2605.29926 · v1 · pith:2AA6CWM2new · submitted 2026-05-28 · 💻 cs.LG

A Triple-Modal Contrastive Learning Framework with Sequence, Graph, and 3D Features for Drug-Target Interaction Prediction

Le Xu , Xi Zhang , Dan Luo , Ting Wang , Xuan Lin This is my paper

Pith reviewed 2026-06-29 08:39 UTC · model grok-4.3

classification 💻 cs.LG
keywords drug-target interaction predictioncontrastive learningmulti-modal learningsequence featuresgraph features3D structuresdrug discoveryfeature alignment
0
0 comments X

The pith

TriMod-DTI combines sequence, graph, and 3D features through contrastive learning to improve drug-target interaction predictions.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper introduces TriMod-DTI as a framework that processes drugs and proteins in three modalities at once to generate richer representations for interaction prediction. It extracts features separately from sequences, graphs, and three-dimensional structures, then applies contrastive learning to pull matching representations of the same molecule closer together while pushing mismatched ones apart. The goal is to capture complementary information that single-modality or dual-modality models miss. Experiments on three standard datasets show higher accuracy than prior methods, and ablations confirm that removing any modality or the alignment step reduces performance. The authors position the work as a step toward more reliable computational support for identifying drug candidates.

Core claim

TriMod-DTI is a triple-modal contrastive learning framework that incorporates 1D sequences, 2D graphs, and 3D structures of drugs and proteins, obtaining the universal and complementary feature representations for DTI prediction. A Feature Extractor captures drug and target features across the three modalities. A triple-modal contrastive learning strategy aligns different modal representations of the same drug or protein in the latent space by constructing cross-modal positive and negative sample pairs, thereby enhancing the model's discriminative ability.

What carries the argument

The triple-modal contrastive learning strategy that aligns representations from sequence, graph, and 3D modalities of the same drug or protein through cross-modal positive and negative pairs.

If this is right

  • The model outperforms state-of-the-art methods on three benchmark datasets for DTI prediction.
  • Ablation studies confirm that each of the three modalities contributes to overall performance.
  • Case studies demonstrate practical utility for identifying potential drug-target pairs in drug discovery workflows.
  • The framework produces enriched representations by integrating information across 1D, 2D, and 3D views that prior single- or dual-modal approaches overlook.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • The same alignment approach might transfer to other bioinformatics tasks that already have access to sequence, graph, and structural data, such as protein-protein interaction prediction.
  • If the contrastive step reduces reliance on large labeled sets, follow-up work could test performance in low-data regimes typical of rare targets.
  • Adding a fourth modality, such as textual descriptions from literature, could be tested as a direct extension of the current three-way alignment design.

Load-bearing premise

The three modalities supply complementary rather than redundant information and the contrastive alignment step meaningfully improves downstream DTI prediction accuracy.

What would settle it

Training the same model on the benchmark datasets after removing the contrastive alignment component and observing no drop in prediction metrics would falsify the contribution of the alignment step.

Figures

Figures reproduced from arXiv: 2605.29926 by Dan Luo, Le Xu, Ting Wang, Xi Zhang, Xuan Lin.

Figure 1
Figure 1. Figure 1: The cosine similarity between the embeddings of different modalities. [PITH_FULL_IMAGE:figures/full_fig_p002_1.png] view at source ↗
Figure 2
Figure 2. Figure 2: Illustration of TriMod-DTI. (a) The framework of proposed TriMod [PITH_FULL_IMAGE:figures/full_fig_p004_2.png] view at source ↗
Figure 3
Figure 3. Figure 3: Performance of each modality encoded independently on the GPCR. [PITH_FULL_IMAGE:figures/full_fig_p009_3.png] view at source ↗
Figure 4
Figure 4. Figure 4: Parameter sensitivity analysis for TriMod-DTI on GPCR dataset. [PITH_FULL_IMAGE:figures/full_fig_p009_4.png] view at source ↗
Figure 5
Figure 5. Figure 5: Visualization of drug-protein interactions. [PITH_FULL_IMAGE:figures/full_fig_p010_5.png] view at source ↗
read the original abstract

Accurate prediction of drug-target interactions (DTI) is critical for drug discovery. Existing methods often rely on single-modal representations (e.g., sequences or graphs) or combine only two modalities, overlooking 3D structural features. To address this challenge, we propose TriMod-DTI, a triple-modal contrastive learning framework that incorporates 1D sequences, 2D graphs, and 3D structures of drugs and proteins, obtaining the universal and complementary feature representations for DTI prediction. We design a Feature Extractor to capture drug and target features across the three modalities, thereby enriching their representations. We further propose a triple-modal contrastive learning strategy to align different modal representations of the same drug or protein in the latent space. By constructing cross-modal positive and negative sample pairs, this approach enhances the model's discriminative ability. Experiments on three benchmark datasets demonstrate that TriMod-DTI outperforms state-of-the-art methods. The ablation studies validate the contributions of each modality. Moreover, case studies highlight its practical potential for DTI prediction and drug discovery.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 0 minor

Summary. The manuscript proposes TriMod-DTI, a triple-modal contrastive learning framework for drug-target interaction (DTI) prediction. It integrates 1D sequence, 2D graph, and 3D structural features of drugs and proteins via a Feature Extractor module and a triple-modal contrastive learning strategy that aligns representations of the same entity across modalities using cross-modal positive/negative pairs. The central empirical claim is that the model outperforms state-of-the-art methods on three benchmark datasets, with ablation studies confirming the contribution of each modality and case studies illustrating practical utility for drug discovery.

Significance. If the reported gains are reproducible and arise from genuine complementarity among the three modalities rather than implementation artifacts, the work would provide a useful demonstration that 3D structural information can be productively combined with sequence and graph modalities via contrastive alignment for DTI. The ablation studies, if they include proper controls, would strengthen the case for multi-modal over uni- or bi-modal baselines. However, the absence of any quantitative metrics, dataset sizes, statistical tests, or implementation details in the provided text makes it impossible to gauge the magnitude or robustness of the claimed advance.

major comments (2)
  1. [Abstract] Abstract: The claim that 'Experiments on three benchmark datasets demonstrate that TriMod-DTI outperforms state-of-the-art methods' supplies no numerical results (e.g., AUC, AUPR, or accuracy deltas), no baseline names, no dataset identifiers or sizes, and no mention of statistical significance or multiple-run variance. This renders the central empirical claim unverifiable from the manuscript as presented.
  2. [Abstract] Abstract: The statement that 'ablation studies validate the contributions of each modality' does not report the quantitative effect sizes of removing each modality or the controls used (e.g., whether the contrastive loss is ablated independently of the feature extractor). Without these numbers, it is impossible to determine whether the modalities are complementary or largely redundant.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for these comments on the abstract. We agree that the abstract would benefit from greater specificity regarding quantitative results and controls. We will revise the abstract in the next version of the manuscript to incorporate the requested details while preserving its concise nature. Point-by-point responses follow.

read point-by-point responses

  1. Referee: [Abstract] Abstract: The claim that 'Experiments on three benchmark datasets demonstrate that TriMod-DTI outperforms state-of-the-art methods' supplies no numerical results (e.g., AUC, AUPR, or accuracy deltas), no baseline names, no dataset identifiers or sizes, and no mention of statistical significance or multiple-run variance. This renders the central empirical claim unverifiable from the manuscript as presented.

    Authors: We agree that the abstract, in its current form, does not include these specifics. In the revised manuscript we will update the abstract to report the key performance deltas (AUC and AUPR), the names of the primary state-of-the-art baselines, the identifiers and approximate sizes of the three benchmark datasets, and a statement on statistical significance derived from multiple independent runs with reported standard deviation. These quantitative comparisons and variance estimates already appear in the experimental results section with accompanying tables; the revision will simply surface the most salient figures in the abstract itself. revision: yes

  2. Referee: [Abstract] Abstract: The statement that 'ablation studies validate the contributions of each modality' does not report the quantitative effect sizes of removing each modality or the controls used (e.g., whether the contrastive loss is ablated independently of the feature extractor). Without these numbers, it is impossible to determine whether the modalities are complementary or largely redundant.

    Authors: We accept this observation. The revised abstract will include the observed effect sizes (e.g., the AUC drop when each modality is removed) and will explicitly state that the contrastive loss was ablated independently of the feature extractor to isolate its contribution. The full ablation tables, which already contain these controls and quantitative deltas, are presented in the experiments section; the abstract revision will summarize the principal effect sizes to demonstrate complementarity. revision: yes

Circularity Check

0 steps flagged

No significant circularity identified

full rationale

The paper is an empirical ML methods contribution whose central claims consist of experimental outperformance on three benchmark DTI datasets plus ablation results validating each modality. No derivation chain, equations, fitted parameters, or uniqueness theorems are present in the provided text. The performance statements are external empirical assertions that do not reduce to any self-definition, self-citation load-bearing premise, or renaming of known results; they rest on standard train/test splits and baseline comparisons outside the model's internal construction.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

Abstract supplies no information on free parameters, axioms, or invented entities.

pith-pipeline@v0.9.1-grok · 5726 in / 931 out tokens · 21662 ms · 2026-06-29T08:39:18.731282+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

23 extracted references · 17 canonical work pages · 2 internal anchors

  1. [1]

    IEEE/ACM Transactions on Computational Biology and Bioinformatics19(4), 2092–2110 (2021).https://doi.org/10.1109/TCBB.2021.3069040

    Zhao, Q., Yang, M., Cheng, Z., Li, Y., Wang, J.: Biomedical data and deep learn- ing computational models for predicting compound-protein relations. IEEE/ACM Transactions on Computational Biology and Bioinformatics19(4), 2092–2110 (2021).https://doi.org/10.1109/TCBB.2021.3069040

    work page doi:10.1109/tcbb.2021.3069040 2092

  2. [2]

    Nature Reviews Drug Discovery1(11), 882–894 (2002).https://doi.org/10.1038/nrd898

    Bajorath, J.: Integration of virtual and high-throughput screening. Nature Reviews Drug Discovery1(11), 882–894 (2002).https://doi.org/10.1038/nrd898

    work page doi:10.1038/nrd898 2002

  3. [3]

    In: Drug Discovery and Evaluation (2024).https://doi.org/ 10.1016/B978-0-323-99596-5.00068-8

    Mak, K.-K., Wong, Y.-H., Pichika, M.R.: Artificial intelligence in drug discovery and development. In: Drug Discovery and Evaluation (2024).https://doi.org/ 10.1016/B978-0-323-99596-5.00068-8

    work page doi:10.1016/b978-0-323-99596-5.00068-8 2024

  4. [4]

    Bioinformatics36(16), 4406–4414 (2020).https://doi.org/ 10.1093/bioinformatics/btaa524

    Chen, L., Tan, X., Wang, D., Zhong, F., Liu, X., Yang, T., Luo, X., Chen, K., Jiang, H., Zheng, M.: TransformerCPI: improving compound–protein interaction prediction by sequence-based deep learning with self-attention mechanism and label reversal experiments. Bioinformatics36(16), 4406–4414 (2020).https://doi.org/ 10.1093/bioinformatics/btaa524

    work page doi:10.1093/bioinformatics/btaa524 2020

  5. [5]

    Bioinformatics 37(8), 1140–1147 (2021).https://doi.org/10.1093/bioinformatics/btab040

    Nguyen, T., Le, H., Quinn, T.P., Nguyen, T., Le, T.D., Venkatesh, S.: GraphDTA: predicting drug–target binding affinity with graph neural networks. Bioinformatics 37(8), 1140–1147 (2021).https://doi.org/10.1093/bioinformatics/btab040

    work page doi:10.1093/bioinformatics/btab040 2021

  6. [6]

    IEEE Transactions on Neural Networks20(1), 61–80 (2008)

    Scarselli, F., Gori, M., Tsoi, A.C., Hagenbuchner, M., Monfardini, G.: The graph neural network model. IEEE Transactions on Neural Networks20(1), 61–80 (2008). https://doi.org/10.1109/TNN.2008.2005605

    work page doi:10.1109/tnn.2008.2005605 2008

  7. [7]

    Brief- ings in Bioinformatics23(4), bbac272 (2022).https://doi.org/10.1093/bib/ bbac272

    Yazdani-Jahromi, M., Yousefi, N., Tayebi, A., Kolanthai, E., Neal, C.J., Seal, S., Garibay, O.O.: AttentionSiteDTI: an interpretable graph-based model for drug- target interaction prediction using NLP sentence-level relation classification. Brief- ings in Bioinformatics23(4), bbac272 (2022).https://doi.org/10.1093/bib/ bbac272

    work page doi:10.1093/bib/ 2022

  8. [8]

    Mathematical Biosciences and Engineering20(6), 10610–10625 (2023)

    Wen, J., Gan, H., Yang, Z., Zhou, R., Zhao, J., Ye, Z.: Mutual-DTI: A mutual inter- action feature-based neural network for drug-target protein interaction prediction. Mathematical Biosciences and Engineering20(6), 10610–10625 (2023)

    2023

  9. [9]

    Computational Biology and Chemistry118, 108449 (2025)

    Li, C., Mi, J., Wang, H., Liu, Z., Gao, J., Wan, J.: MGMA-DTI: Drug target in- teraction prediction using multi-order gated convolution and multi-attention fusion. Computational Biology and Chemistry118, 108449 (2025)

    2025

  10. [10]

    Semi-Supervised Classification with Graph Convolutional Networks

    Kipf, T.N., Welling, M.: Semi-supervised classification with graph convolutional networks. arXiv preprint arXiv:1609.02907 (2016)

    work page internal anchor Pith review Pith/arXiv arXiv 2016

  11. [11]

    Anarci: antigen receptor numbering and re- 117 ceptor classification.Bioinformatics, 32(2):298–300, 2016

    Cheng, Z., Zhao, Q., Li, Y., Wang, J.: IIFDTI: predicting drug–target interactions through interactive and independent features based on attention mechanism. Bioin- formatics38(17), 4153–4161 (2022).https://doi.org/10.1093/bioinformatics/ btac485

    work page doi:10.1093/bioinformatics/ 2022

  12. [12]

    Lin, X., Zhang, X., Yu, Z.-G., Long, Y., Zeng, X., Philip, S.Y.: CSCL-DTI: pre- dicting drug-target interaction through cross-view and self-supervised contrastive learning.In:2024IEEEInternationalConferenceonBioinformaticsandBiomedicine (BIBM), pp. 707–712. IEEE (2024).https://doi.org/10.1109/BIBM62325.2024. 10821786

    work page doi:10.1109/bibm62325.2024 2024

  13. [13]

    In: International Conference on Machine Learning, pp

    Radford, A., Kim, J.W., Hallacy, C., Ramesh, A., Goh, G., Agarwal, S., Sastry, G., Askell, A., Mishkin, P., Clark, J., et al.: Learning transferable visual models from natural language supervision. In: International Conference on Machine Learning, pp. 8748–8763. PMLR (2021)

    2021

  14. [14]

    Landrum, G., et al.: RDKit: A software suite for cheminformatics, computational chemistry, and predictive modeling (2013)

    2013

  15. [15]

    bioRxiv (2022).https://doi.org/10.1101/2022.07.21.500999

    Wu, R., Ding, F., Wang, R., Shen, R., Zhang, X., Luo, S., Su, C., Wu, Z., Xie, Q., Berger, B., et al.: High-resolution de novo structure prediction from primary sequence. bioRxiv (2022).https://doi.org/10.1101/2022.07.21.500999

    work page doi:10.1101/2022.07.21.500999 2022

  16. [16]

    Bioinformatics37(6), 830–836 (2021)

    Huang, K., Xiao, C., Glass, L.M., Sun, J.: MolTrans: molecular interaction trans- former for drug–target interaction prediction. Bioinformatics37(6), 830–836 (2021). https://doi.org/10.1093/bioinformatics/btaa880

    work page doi:10.1093/bioinformatics/btaa880 2021

  17. [17]

    In: Advances in Neural Information Processing Systems, vol

    Vaswani,A.,Shazeer,N.,Parmar,N.,Uszkoreit,J.,Jones,L.,Gomez,A.N.,Kaiser, Ł., Polosukhin, I.: Attention is all you need. In: Advances in Neural Information Processing Systems, vol. 30, pp. 1–11. Curran Associates, Inc. (2017)

    2017

  18. [18]

    arXiv preprint arXiv:2405.20358 (2024)

    Mu, S., Liang, S., Li, X.: Medication Recommendation via Dual Molecular Modali- ties and Multi-Substructure Enhancement. arXiv preprint arXiv:2405.20358 (2024). https://doi.org/10.1016/j.eswa.2025.127163

    work page doi:10.1016/j.eswa.2025.127163 2024

  19. [19]

    arXiv preprint arXiv:2009.01411 (2020)

    Jing, B., Eismann, S., Townshend, R.J.L., Dror, R.: Learning from protein struc- ture with geometric vector perceptrons. arXiv preprint arXiv:2009.01411 (2020). https://doi.org/10.48550/arXiv.2009.01411

    work page doi:10.48550/arxiv.2009.01411 2009

  20. [20]

    BMC Structural Biology14, 1–9 (2014).https://doi.org/10

    Saberi Fathi, S.M., Tuszynski, J.A.: A simple method for finding a protein’s ligand- binding pockets. BMC Structural Biology14, 1–9 (2014).https://doi.org/10. 1186/1472-6807-14-18

    2014

  21. [21]

    Topology Adaptive Graph Convolutional Networks

    Du, J., Zhang, S., Wu, G., Moura, J.M.F., Kar, S.: Topology adaptive graph convo- lutional networks. arXiv preprint arXiv:1710.10370 (2017).https://doi.org/10. 48550/arXiv.1710.10370

    work page internal anchor Pith review Pith/arXiv arXiv 2017

  22. [22]

    Bioinformat- ics25(11), 1422 (2009).https://doi.org/10.1093/bioinformatics/btp163

    Cock, P.J.A., Antao, T., Chang, J.T., Chapman, B.A., Cox, C.J., Dalke, A., Fried- berg, I., Hamelryck, T., Kauff, F., Wilczynski, B., et al.: Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformat- ics25(11), 1422 (2009).https://doi.org/10.1093/bioinformatics/btp163

    work page doi:10.1093/bioinformatics/btp163 2009

  23. [23]

    Bioinformatics38(Supplement_2), ii68–ii74 (2022).https://doi.org/10.1093/bioinformatics/btac470

    You, Y., Shen, Y.: Cross-modality and self-supervised protein embedding for com- pound–protein affinity and contact prediction. Bioinformatics38(Supplement_2), ii68–ii74 (2022).https://doi.org/10.1093/bioinformatics/btac470

    work page doi:10.1093/bioinformatics/btac470 2022